Objective To examine the relationship between anti-M€ ullerian hormone (AMH) and the severity of the phenotype of patients with polycystic ovary syndrome (PCOS) and whether AMH can act as a diagnostic marker for PCOS? Design A prospective diagnostic utility study of AMH as a marker of PCOS. Patients A consecutive series of women presenting to a tertiary infertility clinic (n = 164) plus a second series of women prepared for assisted conception treatments (n = 89) recruited between June 2012 and May 2013. Measurements Polycystic ovary syndrome was diagnosed using the Rotterdam criteria. AMH was measured using the Generation II assay (Beckman Coulter). The diagnostic utility of AMH was established using receiver operator characteristic (ROC) curves. Cut-off values for the individual features of PCOS are proposed. Results There was a significant difference in serum AMH concentration in women with normal ovaries (13Á2 pmol/l), polycystic ovary morphology (PCOM) alone (37Á8 pmol/l) and PCOS (53Á2 pmol/l). Follicle number, increasing cycle length and evidence of hyperandrogenism were all independently associated with serum AMH concentration (P < 0Á01). AMH was significantly affected by the different phenotypic presentations of PCOS with those with all components (PCOM, HA and OA) having the highest mean value [72Á7 pmol/l (P < 0Á01)]. Conclusions Serum AMH has the capacity to act as a diagnostic test for PCOS. Moreover, since its value rises with the more marked phenotypes, different cut-off values need to be used to differentiate those patients with polycystic ovarian morphology (PCOM), hyperandrogenism (HA) and oligoanovulation (OA).
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disturbance to affect women of reproductive years. Despite the agreed Rotterdam consensus on the definition and diagnosis of PCOS, 1 some believe that hyperandrogenism (HA) should remain an integral part of the diagnosis, 2 although this term encompasses both biochemical and clinical HA which are both notoriously difficult to define and measure with accuracy. 3 In an attempt to reunite these viewpoints, it has been suggested that a measurement of anti-M€ ullerian hormone (AMH) may provide the perfect unifier. 4 Anti-M€ ullerian hormone, a dimeric glycoprotein, is a member of the transforming growth factor-beta superfamily of regulatory proteins. 5 In females, the physiological role of AMH involves inhibition of primordial follicle recruitment and it acts as sentinel for follicle oestrogen production. 5 AMH is exclusively produced by the granulosa cells of the pre-antral and antral follicles. It is widely recognized that women with PCOS have an elevated serum AMH concentration, not singularly related to the increased follicle pool but also the increased production per follicle. 6, 7 There is now significant evidence supporting the correlation between AMH, oligoanovulation (OA) and HA. 5, 8 Anti-M€ ullerian hormone has been implicated in the follicular dysfunction that leads to the development of PCOS. 8 Defective selection of the lead follicle culminates in anovulation and a relative stockpiling of growing follicles. The usual inhibition of follicle recruitment 9,10 is lost. The intra-ovarian environment, in particular the androgen concentration, is also thought to play a role in the pathophysiology of PCOS. 11 Luteinizing hormone (LH) propagates this effect; indeed, when granulosa cells are cultured with LH, there is an increased expression of AMH in anovulatory polycystic ovaries, not seen in normal ovaries. 12 Hyperinsulinaemia and insulin resistance (IR) may act as a 'second hit' on the already dysregulated system by amplification of intra-ovarian HA, with insulin acting as a 'co-gonadotrophin'.
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Objective
This study assesses the diagnostic potential of AMH for PCOS and its ability to reflect the severity of the syndrome. Despite a wide literature on increased AMH in PCOS, there is little consensus on an appropriate reference range. The unification of different assays to form the single Generation II (Beckman Coulter) assay has provided a stepping stone towards a much needed international standardization. Few publications 13, 14 have used the Gen II assay in the diagnosis of PCOS. This study therefore aims to provide further statistically relevant information, to aid interpretation and dissemination of evidence in support of AMH as a diagnostic tool for PCOS.
Subjects and methods
Between Of the total population, 102 had PCOS, 42 had isolated PCOM, and the remaining 109 had no features of PCOS with normal ovaries. The PCOS groups were further categorized into the four distinct phenotypes: OA/HA, OA/PCOM, HA/PCOM and OA/ HA/PCOM.
Assay
The AMH assay used was the Beckman Coulter Generation II ELISA kit (Gen II ELISA A79765; Beckman Coulter Inc., High Wycombe, UK). The interassay CV was 8Á2% at 20Á6 pmol/l and 12Á3% at 66Á2 pmol/L. All samples were processed following the June 2013 field safety notice published by Beckman Coulter, 16 implementing the dilution step prior to addition to the ELISA plate. This was to negate interference from complement activity that could erroneously lower the reported AMH levels by up to 70%. Samples were stored at À20°C for a maximum 18 months. Testosterone and androstenedione were measured by LC-MS-MS. 15 The testosterone interassay CV was 5Á3% at 0Á8 nmol/l and 5Á3% at 3Á5 nmol/l. The androstenedione interassay CV was 6Á5% at 3Á5 nmol/l and 6Á8% at 8Á7 nmol/l. The full details of all laboratory assays used can be seen in the Table S1 .
Statistical analysis
Statistics were calculated using IBM SPSS 21 (IBM Corporation, New York, NY, USA) statistics package. Descriptive statistics used the complete cohort and diagnostic receiver operator characteristic (ROC) tests used the consecutive series only. Descriptive statistics included mean with standard deviation, median with interquartile range (IQR) and geometric mean with 95% confidence intervals (CI). Continuous data were tested for normality using Kolmogorov-Smirnov test. Positively skewed data were log-transformed prior to testing and then back-transformed for interpretation. Statistical tests included the t-test, one-way analysis of variance (ANOVA), nonparametric Mann-Whitney Uor Kruskal-Wallis tests and multiple regression analysis. Contingency tables used Fisher's exact statistic. A P-value <0Á01 was considered significant. ROC curves were used to assess the diagnostic performance of AMH in the diagnosis of PCOS.
Ethical approval
This was a single-centre, prospective observational study with permission from Leeds West Ethics Committee (12/LO/0679).
Results
All patients
Patients meeting the Rotterdam diagnostic criteria for PCOS comprised 40% of the study population. The demographics for women categorized by PCOS status are shown in Table 1 . There was a significant difference in AMH concentration between those with normal ovaries and PCOS. Women presenting with PCOS were significantly younger with a lower mean FSH but increased LH and testosterone concentrations. Women with isolated PCOM represented a group in between normal and PCOS women. Follicle number, increasing cycle length and evidence of HA were all independent predictors of AMH using multiple regression analysis. There was no difference in AMH by ethnic group, including individual comparison of the two largest populations of White Caucasian (n = 210) and South Asian (n = 34) (26Á9 (23Á7-30Á5 95% CI) pmol/l vs 35Á0 (25Á3-48Á6 95% CI) pmol/l; P = 0Á13, t-test). Anti-M€ ullerian hormone was significantly different in the different phenotypic presentations of PCOS ( Fig. 1) with those with the most severe form of PCOS, that is with all components (PCOM, HA and OA) having the highest value. No difference was seen between those who had PCOM and either OA or HA [41Á4 (31Á4-54Á5 95% CI) pmol/l vs 44Á7 (33Á6-59Á5 95% CI) pmol/l; P = 0Á69, t-test]. The OA/HA group was too small (n = 4) to make any useful comparisons. Significant variation occurred across the groups in BMI and testosterone levels. Those with all three components had a heavier BMI and a more androgenic profile. Overall, any PCOS phenotype had an elevated BMI and testosterone compared with those without PCOS.
Consecutive series for diagnostic performance studies Figure 2 presents a ROC curve comparing different hormonal tests and AFC to diagnose PCOS on the consecutive series. The control group includes any women with an isolated feature of PCOS, that is isolated PCOM without either hyperandrogenism or oligoanovulation to best reflect the population studied. AMH had a significantly increased (P ≤ 0Á05) area under the curve (AUC) (0Á84) when compared with testosterone (0Á74), AFC (0Á72) or androstenedione (0Á65). Using Youden's index in separate ROC analyses, the best compromise between sensitivity and specificity suggests 29 pmol/l (88Á1%, 73Á2%; AUC 0Á84) and 45 pmol/l (67%, 57%) to distinguish between firstly, those with or without PCOS and secondly, asymptomatic PCOM and PCOS. If ROC curves are constructed for the phenotypes, AMH has an enhanced AUC for OA/HA/PCOM (0Á84) vs PCOM/OA (0Á60). Further use of ROC curve analysis revealed AMH had a higher diagnostic potential in the older age groups. It is recognized that AMH falls with age so the use of age-related cut-offs need to be considered. 17 Anti-M€ ullerian hormone can be used in replacement of each of the three Rotterdam criteria. By simple substitution of PCOM with an AMH of ≥29 pmol/l, there was no difference in the proportion of patients diagnosed with PCOS using Fisher's exact test. If an AMH of ≥29 pmol/l was substituted for either OA or HA, using PCOM as the second defining feature of PCOS, a significant difference in proportion was evident. If an AMH of ≥45 pmol/l was used, instead this significance was lost.
Discussion
The main finding of this study is the significant correlation between AMH and all components of the PCOS diagnosis (PCOM, OA and HA), even when adjusted for BMI. This supports two previous studies 18, 19 which both found an independent association between AMH, number of small antral follicles and serum androgens. Furthermore, this supports the notion that the origin of PCOS resides within the ovary but is influenced by outside factors such as circulating levels of insulin and luteinizing hormone. 13 The positive association between AFC and AMH is clearly replicated within this trial. 20, 24 This correlation is confirmed with the high AUC of 0Á90 for AMH diagnostics for PCOM alone. Such a significant parallel has led many to suggest that AMH can replace or act as an alternative for AFC.
19,21,22
Dewailly et al. 4 show that AFC and AMH are strong markers of an ovarian anomaly. Sahmay et al. 23 argue that PCOM is the most effective factor affecting serum AMH levels. The editorial by Raine-Fenning 24 summarizes this argument, with the stance that AMH and USS 'are unlikely to offer mutually exclusive information'. Using the proposed AMH cut-off of ≥29 pmol/l as a replacement for PCOM, there was no difference between the proportions of women diagnosed with different combinations of PCOS. This study raises a novel possibility in the diagnostic process with two tiers for AMH replacement. For pure PCOM substitution, 29 pmol/l could be used; but if USS is the only feature, a higher AMH threshold (45 pmol/l) could be used as a surrogate for either OA or HA. This would support the findings of Dewailly 4 who suggested that follicle number and serum AMH could be used as a surrogate marker for HA.
Our data using ROC analysis in a consecutive series of patients suggest that ≥29 pmol/l and ≥45 pmol/l can be used to distinguish between women with or without PCOS and those with isolated PCOM and PCOS. The diagnostic utility of AMH in PCOS is encouraging with an AUC of 0Á84. Recruiting patients from a tertiary infertility clinic population is a limitation of our study as will not reflect the incidence of PCOS in the general population. A meta-analysis of the diagnostic utility of AMH for PCOS produces a similar result (4Á7 ng/ml) to the current recommendation (4Á06 ng/ml, using the conversion factor pmol/l = lg/l 9 7Á143). 25 Our study deliberately keeps the isolated PCOM population in our control group unlike others, 13 due to its high incidence in the general 'normal' population. This reduces the specificity of our proposed AMH thresholds (e.g. 45 pmol/l asymptomatic PCOM vs PCOS; sensitivity 67% specificity 57%). Using the same example, if the isolated PCOM population are removed, the corresponding specificity of the test is artificially improved (94Á2%). The ROC curve is also improved with an AUC of 0Á92. Improved ultrasound technology has led to recommendations to increase the threshold follicle number for the diagnosis of PCOM. 21, 26 A consensus as to whether the new threshold should be increased to 25 or 28 follicles 27,28 if the maximum ultrasound probe frequency exceeds 8 MHz remains to be decided. AMH offers an attractive option to be used either in conjunction with ultrasound or even alone for the diagnosis of PCOS, as long as ongoing assay stability issues can be resolved. 29 Furthermore, with the move towards a fully automated AMH assay, it has been suggested that a lower reference level be used for PCOS diagnosis when compared with the manual assay, as used in this study. 30 There is a downward trend in AMH with age, reflecting reduced ovarian reserve. 31 Wiser et al. 32 have produced a nomogram for AFC in PCOS. Their retrospective review shows a slower decline in AFC with age in women with PCOS at a rate of 0Á8 follicles/year in PCOS and 1Á7 follicles/year in non-PCOS (P < 0Á001). Our study provides support for this theory. The diagnostic performance of AMH seemingly improves with advancing age. The AUC for the under 25 years vs the over 35 years was noticeably different (0Á74 vs 0Á91). Younger women have an elevated AFC which is not related to PCOM or PCOS. There is also a greater preponderance of PCOM without the other manifestations of PCOS. The phenotypic presentation of PCOS alters with advancing age, with many women developing a regular menstrual cycle 33 and a decline in HA. 34 Women presenting with PCOS are often younger and many will have achieved a pregnancy whilst relatively young. 35 We might speculate that those who present later have a potentially more pronounced form of PCOS and therefore may have an increased serum concentration of AMH.
In conclusion, AMH is a useful tool in the diagnostic armamentarium for PCOS. The serum concentration of AMH is closely related to AFC, hyperandrogenism and anovulation. AMH can be on the whole interchanged for any of the Rotterdam criteria, but perhaps most effectively for PCOM. AMH reflects severity of disease with those exhibiting the full constellation of symptoms having the highest levels. Further attempts to provide cut-off levels suggest ≥29 pmol/l for PCOS and a higher level of ≥45 pmol/l to separate PCOM from PCOS. With advancing age, AMH has an improved diagnostic ability for PCOS. AMH lies within the foundations of PCOS and with further scientific work, its exact contribution to the underlying pathophysiology of the condition may be elucidated. It is important to recognize that the manual Gen II assay results may not necessarily be extrapolated to other assay techniques, such as the current automated platform in use for AMH. In the meantime, AMH is a hormonal assay that improves upon the traditional tests available in the diagnosis and management of PCOS.
